The size of the Nuclear Imaging Market in the Asia Pacific is forecasted to register a CAGR of 9.64% from 2021 to 2026. As a result, the size of the market is estimated to value USD 6.44 billion by 2026 from USD 4.07 billion in 2021.
Technological developments, expanding diagnostic applications in different diseases such as cancer and cardiovascular diseases, and the increased burden of these chronic diseases are primarily expected to drive the APAC nuclear imaging market expansion. In addition, the region's higher disease incidence raises the requirement for sophisticated technology such as nuclear imaging. These facilities are available because of a significant investment in healthcare infrastructure and medical research. In addition, these countries' per capita incomes are rising, making such technology more affordable. The Asia-Pacific nuclear imaging market has grown due to an increase in the incidence and prevalence of target conditions, advances in imaging methods employing radiopharmaceuticals, and a spike in SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) scans. Aside from data integration, there is a significant possibility to make data available via mobile technology. This allows clinicians to examine and analyze scans from any location. Companies are concentrating on developing systems with integrated technologies due to the benefits and ease of integrated systems and the high demand from doctors.
Additionally, the shift from standalone to hybrid modalities, advances in radiotracers, the growing focus on personalized medicine, investments in diagnostic imaging centers through public-private partnerships are expected to generate lucrative growth opportunities for the market to grow during the forecast period. With data integrated, imaging systems, image processing and reconstruction, computer-assisted medical condition diagnosis, 3D picture generation, and the use of appropriate quality control systems are all possible. In addition, physicians may quickly compare scans with data integration to efficiently monitor disease development. In the forecasted period, growing technical developments increased the need for trained experts, increased demand for data integrated imaging systems, and increased demand in this nation will all offer new opportunities for the nuclear imaging equipment market.
The key restraints for the APAC nuclear imaging market include increased research and development costs, the greater cost of nuclear imaging systems, and highly advanced hybrid nuclear imaging equipment. The market's growth is expected to be hampered by the short half-life of radiopharmaceuticals, supply instability, logistical challenges, and rigorous regulatory rules, as well as competition from traditional alternative diagnostic techniques. The radioactive Tc99m (technetium 99), which is the most widely used isotope for imaging the body in nuclear medicine scans, is now in low supply in nuclear imaging, which is one of the significant challenges to the market.
This research report on the Asia Pacific Nuclear Imaging Market has been segmented & sub-segmented into the following categories:
By Product:
By Application:
By End-User:
By Country:
Regional Analysis:
During the forecast period, the Asia Pacific area is predicted to have the greatest CAGR. The significant rise in this region can be due to rising chronic disease incidence, increased awareness of the advantages of early disease detection, and improved healthcare systems in the region. Due to the growing incidence of cancer and other chronic illnesses, increased awareness of early cancer detection, increased demand for nuclear medicine equipment, and the availability of unexplored opportunities, Asia-Pacific has large market potential. In addition, the Asia Pacific area has the world's most populated countries, such as China and India, contributing to a significant aging population.
Among Asia-Pacific countries, India, Japan, and Australia are the substantial markets due to growing healthcare budgets and the rising popularity of several radiopharmaceuticals in numerous clinical indications.
KEY MARKET PLAYERS:
Some of the key market participants dominating the APAC Nuclear Imaging market in this region are Mallinckrodt plc, Siemens Medical Solutions, Hitachi Medical Corporation, Medtronic Inc., General Electric Co. (healthcare division), IBA Group, Positron Corporation, Philips Medical Systems, Naviscan, Toshiba Medical Systems Corporation, Carestream Health, Lantheus Medical Imaging Inc., Cardinal Health Inc., and Bayer AG.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Technologies
5.1.1 Introduction
5.1.2 PET Radioisotopes
5.1.2.1 Rubidium-82
5.1.2.2 Fluorine-18
5.1.2.3 Others
5.1.3 SPECT Radioisotopes
5.1.3.1 Thallium-201
5.1.3.2 Technetium-99m
5.1.3.3 Xenon-133
5.1.3.4 Iodine-123
5.1.3.5 Others
5.1.4 Y-o-Y Growth Analysis, By Diagnostic Technologies
5.1.5 Market Attractiveness Analysis, By Diagnostic Technologies
5.1.6 Market Share Analysis, By Diagnostic Technologies
5.2 Application
5.2.1 Introduction
5.2.2 PET
5.2.2.1 Cardiology
5.2.2.2 Oncology
5.2.2.3 Neurology
5.2.2.4 Others
5.2.3 SPECT
5.2.3.1 Lymphoma
5.2.3.2 Neurology
5.2.3.3 Cardiology
5.2.3.4 Thyroid
5.2.3.5 Others
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Technologies
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Technologies
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Technologies
6.1.5.3 By Application
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Mallinckrodt plc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Siemens Medical Solutions
8.3 Hitachi Medical Corporation
8.4 Medtronic Inc.
8.5 General Electric Co. (healthcare division)
8.6 IBA Group
8.7 Positron Corporation
8.8 Philips Medical Systems
8.9 Naviscan
8.10 Toshiba Medical Systems Corporation
8.11 Carestream Health
8.12 Lantheus Medical Imaging Inc.
8.13 Cardinal Health Inc.
8.14 Bayer AG
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
